ReadSense Genomic Center (a part of the TechnoSpark Group of Companies, which operates within the investment network of the Fund for Infrastructure and Educational Programs of the RUSNANO Group) has become the basic analytical laboratory of the LUCARD project on the early cancer metastases detection in July 2020.
Carried out by National BioService, the LUCARD is the first Russian study to assess minimal residual disease (MRD) in lung cancer. The study should determine whether next-generation sequencing (NGS) can be used in analyzing the blood for lung cancer metastases prediction. The research team is working out detection and evaluation techniques for tumor DNA in blood plasma after surgical removal of a stage II-IIIA non-small cell lung cancer (NSCLC). Also, the research on tumor DNA characteristics can help practitioners decide on treatment and estimate its efficiency.
We are involved in the technological part of this great project, which is no less important than medical. While preparing samples, we isolate targeted genes of all the others to identify areas of “mutant” DNA vs. “healthy”. NGS provides a vast array of decrypted data on collected biological samples, forming the basis for correlations with disease development to be traced for the first time ever.
Head of ReadSense Genomic Center Gleb Speshilov
The Lung Cancer Residual Disease study (LUCARD) started in January 2020. The first results are planned to be obtained in the 4th quarter of 2020.
According to oncology.ru, studies estimating lung cancer recurrence risk are being actively conducted in the largest foreign cancer hospitals in France, China, the USA, and the UK. From the intensity of these studies, it appears that the latest trend in oncology and genetics is an attempt to predict the development of recurrence when cancer is diagnosed and operated in the early stages.
ReadSense Genomic Center specializes in developing human genome analysis technologies with the use of next-generation sequencing methods of the 2nd and 3rd generations (NGS and TGS). Also, it carries out complex contract work on a targeted analysis of gene panels.
National BioService (NBS) is the first Russian comprehensive research biobank, founded with the participation of the RVC Biofund. The company is responsible for executing the National Technology Initiative project on the creation of a regional biobank network as a part of the HealthNet Road Map and conducts its own research projects on the creation of tests for the early cancer diagnostics. The company cooperates with more than 125 medical and research centers and has 6 own biobanks and laboratories in 5 regions of the Russian Federation.
Source: Media Office of TechnoSpark